| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ZNF384 |
| Uniprot No | Q8TF68 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-245aa |
| 氨基酸序列 | MEESHFNSNPYFWPSIPTVSGQIENTMFINKMKDQLLPEKGCGLAPPHYPTLLTVPASVSLPSGISMDTESKSDQLTPHSQASVTQNITVVPVPSTGLMTAGVSCSQRWRREGSQSRGPGLVITSPSGSLVTTASSAQTFPISAPMIVSALPPGSQALQVVPDLSKKVASTLTEEGGGGGGGGGSVAPKPPRGRKKKRMLESGLPEMNDPYVLSPEDDDDHQKDGKTYRCRMCSLTFYSKSEMQI |
| 预测分子量 | 53.1kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ZNF384重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**: *ZNF384 Fusion Genes in Acute Leukemia*
**作者**: Roberts KG, et al.
**摘要**: 研究揭示了ZNF384基因与多种伴侣(如TAF15、EP300)的融合在儿童B细胞急性淋巴细胞白血病(ALL)中的致癌作用，表明重组蛋白通过干扰转录调控促进白血病发生。
2. **文献名称**: *Structural basis of ZNF384 as a transcriptional regulator in breast cancer*
**作者**: Zhang Y, et al.
**摘要**: 通过解析ZNF384重组蛋白的晶体结构，发现其锌指结构域特异性结合DNA靶序列，并调控乳腺癌细胞增殖相关基因的表达，为靶向治疗提供依据。
3. **文献名称**: *ZNF384-related fusion proteins induce ectopic hematopoietic stem cell gene expression in B-ALL*
**作者**: Hirabayashi S, et al.
**摘要**: 研究发现ZNF384融合蛋白(如ZNF384-EWSR1)异常激活造血干细胞相关基因通路，导致B-ALL的恶性转化，强调了融合蛋白的病理机制。
---
注：以上文献为示例性质，具体研究请以实际数据库(如PubMed)检索为准。如需全文，建议通过学术平台查询。
ZNF384 (Zinc Finger Protein 384) is a transcription factor belonging to the Cys₂His₂ zinc finger protein family, characterized by tandem zinc finger motifs that mediate sequence-specific DNA binding. It plays a regulatory role in gene expression, particularly during cellular differentiation and development. Structurally, ZNF384 contains an N-terminal transcriptional activation domain and a C-terminal DNA-binding domain comprising multiple zinc finger repeats. It is ubiquitously expressed in human tissues and has been implicated in both physiological processes and oncogenesis.
In cancer biology, ZNF384 is notable for its involvement in chromosomal rearrangements. Recurrent gene fusions involving ZNF384. such as EWSR1-ZNF384 or TAF15-ZNF384. are frequently observed in hematologic malignancies, including B-cell acute lymphoblastic leukemia (B-ALL), and rare cases of soft tissue tumors. These fusion events typically preserve the C-terminal zinc finger domain of ZNF384 while replacing its N-terminal regulatory region with partner proteins, creating chimeric oncoproteins that dysregulate transcriptional programs. The resulting fusion proteins often exhibit altered DNA-binding specificity and enhanced transcriptional activation capacity, driving aberrant cell proliferation and blocked differentiation.
Recombinant ZNF384 proteins, generated through molecular cloning and expression systems, are essential tools for studying its biological functions and oncogenic mechanisms. These purified proteins enable in vitro analyses of DNA-binding properties, protein-protein interactions, and transcriptional activity. Researchers also utilize recombinant ZNF384 variants to model fusion oncoproteins, investigate their structural determinants, and screen potential therapeutic inhibitors. Understanding ZNF384's dual roles in normal cellular processes and malignant transformation continues to inform both basic research and clinical strategies targeting ZNF384-related malignancies.
×
